Advertisement
Screener

PRECIGEN, INC. (PGEN) Net Income (Loss) Attributable to Noncontrolling Interest

PRECIGEN, INC. Net Income (Loss) Attributable to Noncontrolling Interest

PRECIGEN, INC. (PGEN) reported Net Income (Loss) Attributable to Noncontrolling Interest of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-01.

Discontinued › Income Statement › Net Income

us-gaap:NetIncomeLossAttributableToNoncontrollingInterest · last filed 2022-03-01

  • PRECIGEN, INC. net income (loss) attributable to noncontrolling interest for the quarter ending 2020-12-31 was $0.00.
  • PRECIGEN, INC. net income (loss) attributable to noncontrolling interest for the quarter ending 2020-09-30 was $0.00.
  • PRECIGEN, INC. net income (loss) attributable to noncontrolling interest for the quarter ending 2020-06-30 was $0.00.
  • PRECIGEN, INC. net income (loss) attributable to noncontrolling interest for the quarter ending 2020-03-31 was $0.00.
  • PRECIGEN, INC. net income (loss) attributable to noncontrolling interest for fiscal 2021 was $0.00.
  • PRECIGEN, INC. net income (loss) attributable to noncontrolling interest for fiscal 2020 was $0.00.
  • PRECIGEN, INC. net income (loss) attributable to noncontrolling interest for fiscal 2019 was -$1.59M.
  • PRECIGEN, INC. net income (loss) attributable to noncontrolling interest for fiscal 2018 was -$5.37M.
Period endNet Income (Loss) Attributable to Noncontrolling Interest 3 monthNet Income (Loss) Attributable to Noncontrolling Interest 3 month as first filedNet Income (Loss) Attributable to Noncontrolling Interest 6 monthNet Income (Loss) Attributable to Noncontrolling Interest 6 month as first filedNet Income (Loss) Attributable to Noncontrolling Interest 9 monthNet Income (Loss) Attributable to Noncontrolling Interest 12 month
2021-12-31$0.00
10-K · filed 2022-03-01
2020-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01
$0.00
derived: sum of 2 quarters · filed 2022-03-01
$0.00
derived: sum of 3 quarters · filed 2022-03-01
$0.00
10-K · filed 2022-03-01
2020-09-30$0.00
10-Q · filed 2020-11-09
$0.00
derived: sum of 2 quarters · filed 2020-11-09
$0.00
10-Q · filed 2020-11-09
$0.00
derived: sum of 4 quarters · filed 2022-03-01
2020-06-30$0.00
10-Q · filed 2020-08-10
$0.00
10-Q · filed 2020-08-10
$0.00
derived: sum of 3 quarters · filed 2022-03-01
$0.00
derived: sum of 4 quarters · filed 2022-03-01
2020-03-31$0.00
10-Q · filed 2020-05-11
$0.00
derived: sum of 2 quarters · filed 2022-03-01
$0.00
derived: sum of 3 quarters · filed 2022-03-01
-$165.00K
derived: sum of 4 quarters · filed 2022-03-01
2019-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01
$0.00
derived: sum of 2 quarters · filed 2022-03-01
-$165.00K
derived: sum of 3 quarters · filed 2022-03-01
-$1.59M
10-K · filed 2022-03-01
2019-09-30$0.00
10-Q · filed 2020-11-09
-$165.00K
derived: sum of 2 quarters · filed 2020-11-09
-$1.59M
10-Q · filed 2020-11-09
-$2.85M
derived: sum of 4 quarters · filed 2021-03-01
2019-06-30-$165.00K
10-Q · filed 2020-08-10
-$1.59M
10-Q · filed 2020-08-10
-$2.85M
derived: sum of 3 quarters · filed 2021-03-01
-$4.27M
derived: sum of 4 quarters · filed 2021-03-01
2019-03-31-$1.43M
10-Q · filed 2020-05-11
-$2.68M
derived: sum of 2 quarters · filed 2021-03-01
-$4.11M
derived: sum of 3 quarters · filed 2021-03-01
-$5.55M
derived: sum of 4 quarters · filed 2021-03-01
2018-12-31-$1.26M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01
-$2.68M
derived: sum of 2 quarters · filed 2021-03-01
-$4.13M
derived: sum of 3 quarters · filed 2021-03-01
-$5.37M
10-K · filed 2021-03-01
2018-09-30-$1.42M
10-Q · filed 2019-11-12
-$2.87M
derived: sum of 2 quarters · filed 2019-11-12
-$4.11M
10-Q · filed 2019-11-12
-$10.79M
derived: sum of 4 quarters · filed 2020-03-02
2018-06-30-$1.45M
10-Q · filed 2019-08-09
-$2.69M
10-Q · filed 2019-08-09
-$9.37M
derived: sum of 3 quarters · filed 2020-03-02
-$10.52M
derived: sum of 4 quarters · filed 2020-03-02
2018-03-31-$1.24M
10-Q · filed 2019-05-09
-$7.92M
derived: sum of 2 quarters · filed 2020-03-02
-$9.07M
derived: sum of 3 quarters · filed 2020-03-02
-$10.07M
derived: sum of 4 quarters · filed 2020-03-02
2017-12-31-$6.68M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02
-$7.83M
derived: sum of 2 quarters · filed 2020-03-02
-$8.82M
derived: sum of 3 quarters · filed 2020-03-02
-$9.80M
10-K · filed 2020-03-02
2017-09-30-$1.15M
10-Q · filed 2018-11-08
-$2.15M
derived: sum of 2 quarters · filed 2018-11-08
-$3.12M
10-Q · filed 2018-11-08
-$3.90M
derived: sum of 4 quarters · filed 2019-03-01
2017-06-30-$998.00K
10-Q · filed 2018-08-13
-$1.98M
10-Q · filed 2018-08-13
-$2.75M
derived: sum of 3 quarters · filed 2019-03-01
-$3.78M
derived: sum of 4 quarters · filed 2019-03-01
2017-03-31-$978.00K
10-Q/A · filed 2018-08-13
-$1.75M
derived: sum of 2 quarters · filed 2019-03-01
-$2.78M
derived: sum of 3 quarters · filed 2019-03-01
-$3.75M
derived: sum of 4 quarters · filed 2019-03-01
2016-12-31-$775.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01
-$1.80M
derived: sum of 2 quarters · filed 2019-03-01
-$2.77M
derived: sum of 3 quarters · filed 2019-03-01
-$3.66M
10-K · filed 2019-03-01
2016-09-30-$1.03M
10-Q · filed 2017-11-09
-$2.00M
derived: sum of 2 quarters · filed 2017-11-09
-$2.89M
10-Q · filed 2017-11-09
-$3.45M
derived: sum of 4 quarters · filed 2018-03-01
2016-06-30-$967.00K
10-Q · filed 2017-08-09
-$1.86M
10-Q · filed 2017-08-09
-$2.42M
derived: sum of 3 quarters · filed 2018-03-01
-$3.23M
derived: sum of 4 quarters · filed 2018-03-01
2016-03-31-$891.00K
10-Q · filed 2017-05-10
-$1.45M
derived: sum of 2 quarters · filed 2018-03-01
-$2.27M
derived: sum of 3 quarters · filed 2018-03-01
-$3.10M
derived: sum of 4 quarters · filed 2018-03-01
2015-12-31-$561.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01
-$1.38M
derived: sum of 2 quarters · filed 2018-03-01
-$2.21M
derived: sum of 3 quarters · filed 2018-03-01
-$3.50M
10-K · filed 2018-03-01
2015-09-30-$816.00K
10-Q · filed 2016-11-09
-$1.65M
derived: sum of 2 quarters · filed 2016-11-09
-$2.94M
10-Q · filed 2016-11-09
-$3.84M
derived: sum of 4 quarters · filed 2017-03-01
2015-06-30-$831.00K
10-Q · filed 2016-08-09
-$2.12M
10-Q · filed 2016-08-09
-$3.02M
derived: sum of 3 quarters · filed 2017-03-01
-$4.16M
derived: sum of 4 quarters · filed 2017-03-01
2015-03-31-$1.29M
10-Q · filed 2016-05-10
-$2.19M
derived: sum of 2 quarters · filed 2017-03-01
-$3.33M
derived: sum of 3 quarters · filed 2017-03-01
-$4.22M
derived: sum of 4 quarters · filed 2017-03-01
2014-12-31-$899.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01
-$2.04M
derived: sum of 2 quarters · filed 2017-03-01
-$2.93M
derived: sum of 3 quarters · filed 2017-03-01
-$3.79M
10-K · filed 2017-03-01
2014-09-30-$1.14M
10-Q · filed 2015-11-09
-$2.03M
derived: sum of 2 quarters · filed 2015-11-09
-$2.90M
10-Q · filed 2015-11-09
-$3.71M
derived: sum of 4 quarters · filed 2016-02-29
2014-06-30-$892.00K
10-Q · filed 2015-08-10
-$1.76M
10-Q · filed 2015-08-10
-$2.57M
derived: sum of 3 quarters · filed 2016-02-29
-$3.02M
derived: sum of 4 quarters · filed 2016-02-29
2014-03-31-$866.00K
10-Q · filed 2015-05-11
-$1.68M
derived: sum of 2 quarters · filed 2016-02-29
-$2.13M
derived: sum of 3 quarters · filed 2016-02-29
-$2.69M
derived: sum of 4 quarters · filed 2016-02-29
2013-12-31-$814.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29
-$1.26M
derived: sum of 2 quarters · filed 2016-02-29
-$1.82M
derived: sum of 3 quarters · filed 2016-02-29
-$1.93M
10-K · filed 2016-02-29
2013-09-30-$507.00K
10-Q · filed 2014-11-13
-$1.00M
derived: sum of 2 quarters · filed 2014-08-14
-$1.11M
10-Q · filed 2014-11-13
2013-06-30-$556.00K
10-Q · filed 2014-08-14
-$507.00K
10-Q/A · filed 2013-10-21
-$607.00K
10-Q · filed 2014-08-14
-$558.00K
10-Q/A · filed 2013-10-21
2013-03-31-$51.00K
10-Q · filed 2014-05-09
2012-12-31$0.00
10-K · filed 2015-03-02

Similar stocks

Stock NameCountryMarket CapPE Ratio
NewAmsterdam Pharma Co N.V. (NAMS)$2.719B-15.37
MBX Biosciences, Inc. (MBX)United States$2.664B-25.36
Disc Medicine, Inc. (IRON)United States$2.553B-11.40
Immunome Inc. (IMNM)United States$2.538B-9.45
SUPERNUS PHARMACEUTICALS, INC. (SUPN)United States$2.517B-24.63
Nurix Therapeutics, Inc. (NRIX)United States$2.457B-5.39
Dyne Therapeutics, Inc. (DYN)United States$3.084B-7.09
SELLAS Life Sciences Group, Inc. (SLS)United States$2.420B-91.87
uniQure N.V. (QURE)$2.416B-4.93
Vera Therapeutics, Inc. (VERA)United States$2.402B-7.67